Bing Yao, ArriVent Biopharma CEO
With one of biotech's largest private rounds in a year, ArriVent enters PhIII
Bing Yao’s ArriVent Biopharma has amassed a $155 million oversubscribed Series B, crowning it as one of biotech’s largest private rounds in a year-long difficult financing environment.
The proceeds will bankroll a global Phase III study of a drug already approved in China, help ArriVent in-license more molecules and expand the 40-person workforce by another 10 to 20 employees this year, including a chief financial officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
